Our vaccine highly effective against variants prevalent in India, suitable for 12 yrs, above: Pfizer
3 years, 7 months ago

Our vaccine highly effective against variants prevalent in India, suitable for 12 yrs, above: Pfizer

India TV News  

Seeking a fast-track approval for its COVID-19 vaccine, US major Pfizer has told Indian authorities that its jab has shown "high effectiveness" against the SARS-CoV-2 variant prevalent in India and on people of Indian ethnicity or nationality, while it is suitable for everyone aged 12 years or above and can be stored for a month at 2-8 degrees, sources said on Wednesday. Pfizer, which is ready to offer 5 crore doses to India between July and October this year and has sought certain relaxations including indemnification, has held a series of interactions with the Indian government authorities recently including one this week, during which it shared the most recent data points regarding efficacy trials and approvals for its vaccine in various countries and by the World Health Organisation. Govt-Pfizer agree to jointly work to accelerate approval for vaccine Another source privy to the discussions said that following recent meetings between the Indian government and Pfizer's Chairman and CEO Albert Bourla, they have agreed to jointly work on three key issues to accelerate approval for the company's COVID-19 vaccine in India, namely procurement through a central government pathway; indemnity and liability; and the regulatory requirement for post-approval bridging studies. It further said 26 per cent of study participants overall were of "Indian or British Indian" ethnicity, and also included Bangladeshi, Pakistani and any other Asian background, indicating that the observed vaccine effectiveness applies to these groups as well.

India Data Indian Cent Pfizer Pathway Effectiveness Vaccine Effective Indian Ethnicity  yrs  12  india  prevalent  highly  vaccine  effective  data  pathway  efficacy  variants  covid19  cent  indian  suitable  effectiveness  pfizer

History of this topic

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine
4 months, 1 week ago

Recent breakthrough in COVID-19 vaccination: Indian Immunologicals Ltd unveils first needle-free booster vaccine

Hindustan Times  

In a recent development, Hyderabad-based Indian Immunologicals Ltd in collaboration with Griffith University in Australia has made a significant breakthrough in COVID-19 vaccination technology. Indian Immunologicals Ltd unveils first needle-free booster vaccine “This accomplishment signifies a major step forward in our battle against COVID-19. According to the press release, the innovative vaccine sports an attenuated formulation that uses advanced codon …

Global study quantifies rise in blood clots, heart inflammation following COVID-19 vaccination
10 months, 3 weeks ago

Global study quantifies rise in blood clots, heart inflammation following COVID-19 vaccination

The Hindu  

One of the largest assessments of its kind, spanning 99 million people and investigating reports of adverse reactions following COVID-19 vaccination, found that instances of Guillain Barre Syndrome, myocarditis, pericarditis and cerebral venous sinus thrombosis were at least 1.5 times more than expected following inoculation with mRNA and ChadOX1 vaccines. The Global Covid Vaccine Safety Project, which made the assessment, …

With State prod, India can be world leader in vaccines
11 months, 2 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

IISc comes up with warm vaccine against current strains of SARS-CoV-2
1 year ago

IISc comes up with warm vaccine against current strains of SARS-CoV-2

The Hindu  

A heat-tolerant vaccine developed by the Indian Institute of Science researchers is said to be effective against all current strains of SARS-CoV-2 besides having the potential to be quickly adapted for future variants as well. According to IISc-Bengaluru, since the beginning of the COVID-19 pandemic, Prof. Raghavan Varadarajan from the institute’s Molecular Biophysics Unit and collaborators have been working on …

Over 220 crore COVID vaccine doses administered across India, but less than 23 crore booster doses: Health Ministry data
1 year ago

Over 220 crore COVID vaccine doses administered across India, but less than 23 crore booster doses: Health Ministry data

The Hindu  

A total of 220.67 crore COVID vaccine doses have been administered across the country as on December 21 this year, according to data released by the Health Ministry on Wednesday. However, only 22.88 crore precautionary or booster doses have been administered across the country among the eligible adult population. Despite the recent increase of people infected with the JN.1 COVID …

New COVID variant JN.1: Health Ministry says no need for booster dose
1 year ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

A new regime: On the Emergency Use Authorisation regime in India and clinical trials
1 year, 6 months ago

A new regime: On the Emergency Use Authorisation regime in India and clinical trials

The Hindu  

Last week, the Drug Controller General of India cleared, under the provisions of ‘emergency use authorisation’, a new mRNA vaccine for COVID-19 developed by Pune-based Gennova Biopharmaceuticals, a pioneer in India in developing mRNA vaccines. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical Trials Rules, 2019’ that allowed EUA in India for COVID-19 vaccines. …

India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose
1 year, 6 months ago

India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose

The Hindu  

India’s first indigenously developed mRNA vaccine against the dominant Omicron variant of the COVID-19 coronavirus will cost ₹2,292, Sanjay Singh, CEO, Gennova Biopharmaceuticals, said at a press conference on June 24. The vaccine will for now only be available as a booster or “precaution dose”, that is, somebody who has already been vaccinated thrice will be ineligible as the relevant …

India urges G-20 countries to join vaccine research collaborative in wake of COVID vaccine inequity
1 year, 7 months ago

India urges G-20 countries to join vaccine research collaborative in wake of COVID vaccine inequity

The Hindu  

With the COVID-19 pandemic exposing the acute inequity in vaccine development and access, the Indian government is working in partnership with two leading global non-profits to convene and build consensus among the G-20 member States and others, for a proposed Global Vaccine Research Collaborative. “International cooperation is essential to advance vaccine development for emerging pathogens, and the G-20 can serve …

Why It Matters | Does BCG vaccine work for Covid-19 infection?
1 year, 8 months ago

Why It Matters | Does BCG vaccine work for Covid-19 infection?

The Hindu  

What are the facts: The BCG vaccine, typically administered to prevent tuberculosis, did not provide any significant protection against Covid-19 infection to healthcare workers, a new study said. Published in the New England Journal of Medicine, the study’s results stated that 14.7% of the participants who received the bacillus Calmette-Guerin vaccine showed symptoms of Covid-19 infection. In comparison, 12.3% of …

Explained | What are the problems with India’s clinical trials registry?
1 year, 8 months ago

Explained | What are the problems with India’s clinical trials registry?

The Hindu  

The speedy approval of Covid-19 vaccines during the SARS-CoV-2 pandemic spotlighted the importance of clinical trials. Hosted with the Indian Council of Medical Research’s National Institute of Medical Statistics, the CTRI is a free, online public-record system to register clinical trials being conducted in India. The CTRI is one of 17 public trial registries under the International Clinical Trials Registry …

Centre rolls out first nasal Covid vaccine as booster
1 year, 11 months ago

Centre rolls out first nasal Covid vaccine as booster

Hindustan Times  

India on Thursday rolled out the first nasal vaccine against Covid-19, to be administered as a primary or booster dose for adults, potentially widening the pool of people who may take a third vaccine against the infection, cutting tertiary costs, and easing pressures on supply and storage networks. “Being the world’s first intranasal Covid-19 vaccine, this marks a glorious tribute …

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine
1 year, 11 months ago

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine

Hindustan Times  

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 11 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26
1 year, 11 months ago

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26

Hindustan Times  

Bhopal: Bharat Biotech’s nasal Covid-19 vaccine iNCOVACC is expected to be launched on January 26, executive chairman Krishna Ella said at an event on Saturday. “Our nasal vaccine will be officially launched on January 26 on Republic Day,” Ella told students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being …

Time to Join this ‘Herd’: 39% Have Boosted Their Protection against Covid Virus, Finds Survey
1 year, 11 months ago

Time to Join this ‘Herd’: 39% Have Boosted Their Protection against Covid Virus, Finds Survey

News 18  

At least 39% of respondents have already taken the Covid vaccine booster dose, while 6% plan to take the injectable booster and 4% the nasal one, a LocalCircles survey has found. Amid the uptick in Covid in cases in China and other countries, the Centre gave nod for Bharat Biotech’s intranasal COVID vaccine iNCOVAAC as a booster dose. Director General …

Braving a Viral Storm tells the tale of India’s COVID vaccine journey
1 year, 11 months ago

Braving a Viral Storm tells the tale of India’s COVID vaccine journey

The Hindu  

India’s development and production of its own vaccines against COVID-19 was an important part of dealing with the pandemic, pushed by Prime Minister Narendra Modi’s view that the “entrepreneurial state” of government would bear the front-loaded risks of the effort, cushioning the private sector, according to a new book. The authors of Braving a Viral Storm: India’s Covid-19 Vaccine Story, …

Can Your Vaccine Protect You Against BF.7? India Isolates New Strain, Begins Study to Test Efficacy
2 years ago

Can Your Vaccine Protect You Against BF.7? India Isolates New Strain, Begins Study to Test Efficacy

News 18  

A sample of SARS-CoV-2 virus containing the BF.7, a sub-lineage of the Omicron variant, has successfully been isolated by India to assess the efficacy of available vaccines. “Scientists are studying whether the currently available vaccines are effective in preventing infections or serious illness caused by the new sub-variant,” a source was quoted as saying. India has reported at least four …

Staying prepared: On scaling up the pace of COVID-19 genome sequencing
2 years ago

Staying prepared: On scaling up the pace of COVID-19 genome sequencing

The Hindu  

Three years after strict enforcement of its Zero-COVID strategy, China abandoned it abruptly, leading to a jump in cases each day — an estimated 250 million people were infected in 20 days in December, according to the media, overwhelming hospitals and crematoria. Though this variant was found in many countries, including India, months ago, there is fear that the uncontrolled …

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here
2 years ago

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here

Live Mint  

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above according to reports will be available at ₹800+ GST+ hospital charges according to sources. The country’s first intranasal covid vaccine will be rolled out in the fourth week of January as a booster dose for those …

After Slow Start, Demand for Covid-19 Booster Shots Spikes as China's New Wave Triggers Panic in India
2 years ago

After Slow Start, Demand for Covid-19 Booster Shots Spikes as China's New Wave Triggers Panic in India

News 18  

After recording a dull demand for Covid-19 booster shots across months, private hospitals have finally started witnessing footfall and queries to take the jabs. According to Dr Viny Kantroo, Respiratory, Critical Care and Sleep Medicine Consultant, Indraprastha Apollo Hospitals in New Delhi, “With the news of China’s Covid-19 situation, we have seen an uptick in the number of volunteers asking …

Your Best Shot at Fighting Covid: 28% Have Already Taken Booster Dose, Finds Survey
2 years ago

Your Best Shot at Fighting Covid: 28% Have Already Taken Booster Dose, Finds Survey

News 18  

Amid government’s reminders for vaccine boosters in the wake of the Covid uptick in China, 28% of those surveyed by Localcircles said that they “have already taken the booster dose". However, 53% said that they “have not taken the booster dose and do not have any plans of taking it either". After the Centre’s meeting on Wednesday, Niti Aayog’s VK …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use
2 years, 1 month ago

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use

Live Mint  

World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation for restricted use in emergency situations in the age group of 18 and above. A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world's first …

COVID-19 vaccines offer significant protection against reinfection: Study
2 years, 1 month ago

COVID-19 vaccines offer significant protection against reinfection: Study

India TV News  

COVID-19 vaccine: A recent study revealed that people earlier infected with the SARS-CoV-2 virus still benefit from vaccination against COVID-19, gaining 60% to 94% protection against reinfection. “In our study, we find a significant vaccine effectiveness against SARS-CoV-2 reinfection, and this shows the importance of vaccination also for those who might be protected by natural immunity," said Katrine Finderup Nielsen …

Omicron variant of SARS-CoV-2 can evade immunity provided by vaccines: ICMR study
2 years, 2 months ago

Omicron variant of SARS-CoV-2 can evade immunity provided by vaccines: ICMR study

The Hindu  

Omicron, a variant of SARS-CoV-2, can evade immunity provided by vaccines, states a new study published by the Indian Council of Medical Research. Titled ‘Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India’, the study was published on November 2 in Frontiers in Medicine, a peer-reviewed open access medical …

Health Ministry not to procure fresh COVID-19 vaccines; surrenders ₹4,237 crore from vaccination budget
2 years, 2 months ago

Health Ministry not to procure fresh COVID-19 vaccines; surrenders ₹4,237 crore from vaccination budget

The Hindu  

The government’s COVID-19 vaccination programme is in its final leg with the Health Ministry deciding against procuring more vaccines as of now and surrendering ₹4,237 crore, or nearly 85% of the 2022-23 budget allocation for inoculation purposes, to the Finance Ministry. Official sources told PTI that more than 1.8 crore doses are still available with the governments at the Centre …

How the COVID-19 pandemic altered the vaccine story in India
2 years, 2 months ago

How the COVID-19 pandemic altered the vaccine story in India

The Hindu  

Last week, Twitter temporarily blocked a post by Florida’s surgeon general Joseph A. Ladapo. Such DNA vaccines, older in provenance than mRNA vaccines, involve inserting DNA for an antigen — or the part of the virus that stimulates the immune system — into a special kind of circular DNA called plasmids that are usually only found in bacteria. In the …

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences
2 years, 3 months ago

Will Two ‘Made-in-India’ Vaccines Be the New Covid Boosters? News18 Decodes Differences

News 18  

India will soon roll out mRNA shots and intranasal vaccines, which will be available on CoWIN, and can be used as boosters against Covid-19. India’s first mRNA shot is only the third mRNA vaccine to be approved for Covid-19 in the world after Pfizer and Moderna. But mortality will be reduced.” Sharing a study of the intranasal vaccines under clinical …

‘Big boost’: Bharat Biotech’s nasal Covid-19 vaccine gets green light
2 years, 4 months ago

‘Big boost’: Bharat Biotech’s nasal Covid-19 vaccine gets green light

Hindustan Times  

Bharat Biotech's Covid-19 nasal vaccine was cleared for use in adults on Tuesday. The BBV154 intranasal vaccine received emergency use authorisation from the Drugs Controller General of India after it was proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. BBV154 is believed to produce local antibodies in the upper respiratory tract which may provide the …

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use
2 years, 4 months ago

India's First Nasal Vaccine for Covid-19, Made by Bharat Biotech, Cleared for Emergency Use

News 18  

Bharat Biotech has been given an emergency use authorisation by India’s drug regulator, the Drug Controller General of India, for its intranasal Covid-19 vaccine, Union Health Minister Dr Mansukh Mandaviya tweeted on Tuesday. Big Boost to India's Fight Against COVID-19!Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted …

An End to Foreign-return Vaccine Woes: India to Offer Remaining Covid-19 Shots Domestically
2 years, 4 months ago

An End to Foreign-return Vaccine Woes: India to Offer Remaining Covid-19 Shots Domestically

News 18  

Individuals who have received Covid-19 vaccines abroad and wish to get their second dose or booster shot in India can now do so. The development comes following an August 18 report by the Times of India which highlighted the issues people who had been jabbed abroad faced when they tried to receive a second or third shot here because the …

Tackling the new variants
2 years, 4 months ago

Tackling the new variants

Hindustan Times  

The first redesigned coronavirus vaccine was approved for use this week when authorities in the United Kingdom cleared a Moderna dose that the company adapted to create immunity against the Omicron variant. The vaccine is a 50-50 formulation of Moderna’s 2020 product, designed on the Sars-CoV-2 variant that first spread around the world, and of a new dose developed using …

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine
2 years, 4 months ago

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine

Firstpost  

BBV154 has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that helps mass immunisation protect from emerging concern variants Hyderabad, Telangana: Bharat Biotech International on Monday said that BBV154 has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation, …

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
2 years, 4 months ago

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

Deccan Chronicle  

HYDERABAD: Bharat Biotech International Limited on Monday said its COVID-19 intranasal vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. Suchitra K Ella, Joint Managing Director, Bharat Biotech, …

How India Pursued Covid-19 Vaccine Diplomacy Amid Vaccine Nationalism By Rich Nations
2 years, 4 months ago

How India Pursued Covid-19 Vaccine Diplomacy Amid Vaccine Nationalism By Rich Nations

ABP News  

The last 30 months have seen the world getting ravaged by Covid-19. When rich nations of the Global North were stockpiling and hoarding Covid-19 vaccines, many times more than their population, India not only spearheaded one of the largest vaccine drives within the country but also shared the vaccine doses with low- and middle-income countries worldwide. India supplied 23.9 crore …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 5 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month
2 years, 5 months ago

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month

The Hindu  

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of the company, Krishna Ella said. Clinical trials of nasal vaccine complete Mr. Ella said the firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no instance …

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre
2 years, 5 months ago

India supplied 23.9 crore COVID-19 vaccine doses to 101 countries, UN entities: Centre

Firstpost  

Minister of State for Health Bharati Pravin Pawar said as on 19 July, 2022, a total of 200.34 crore COVID-19 vaccine doses have been administered to beneficiaries above 12 years of age in the country New Delhi: India has supplied 23.9 crore doses of coronavirus vaccine to 101 countries and UN entities in the form of grant, commercial export, or …

India crosses milestone of 200 crore vaccinations against COVID-19 in 18 months
2 years, 5 months ago

India crosses milestone of 200 crore vaccinations against COVID-19 in 18 months

The Hindu  

India’s cumulative COVID-19 vaccination drive surpassed the 200-crore milestone on Sunday and as per provisional reports till 1 p.m., a total of 2,00,00,15,631 doses have been administered across the country. It took the country almost nine months to reach the 100-crore mark and another nine months to touch the 200-crore vaccination mark since the start of the drive on January …

Free Covid booster doses will create healthier country: PM Modi
2 years, 5 months ago

Free Covid booster doses will create healthier country: PM Modi

India Today  

Prime Minister Narendra Modi on Wednesday said the government's decision to administer free precautionary doses of Covid-19 vaccines to all citizens aged above 18 will further India's vaccination coverage and create a healthier country. As part of 'Azadi Ka Amrit Mahotsav' celebrations, free precautionary doses of Covid-19 vaccines will be administered to all citizens above the age of 18 at …

Exclusive: Coming soon, second generation, variant specific anti-Covid vaccine
2 years, 5 months ago

Exclusive: Coming soon, second generation, variant specific anti-Covid vaccine

India Today  

The Centre has invested in developing a strain specific vaccine that would help in countering the changing nature of coronavirus. An official who facilitated developing this ecosystem for second generation vaccines told India Today that research and development work is underway to develop strain-specific vaccines in India. A bivalent vaccine will target the specific spike mutations seen in the Omicron …

India's first indigenous mRNA vaccine against Covid gets emergency use nod
2 years, 6 months ago

India's first indigenous mRNA vaccine against Covid gets emergency use nod

India Today  

The Drugs Controller General of India has given a green signal to the country’s first indigenous mRNA vaccine against Covid by Gennova Biopharma for emergency use among adults in India, said sources. While other mRNA vaccines require sub zero temperatures for storage, Gennova Biopharmaceuticals, a Pune-based company, claimed it will not need ultra-cold storages which could mean its roll out …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 6 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study
2 years, 6 months ago

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study

The Hindu  

COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic. In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide, according to …

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed
2 years, 6 months ago

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed

News 18  

Bharat Biotech on Saturday said that the clinical Phase III trials of the nasal vaccine for Covid-19 have been completed and that the company will submit its data with Drugs Controller General of India next month. Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said, if everything is okay, then they will get permission to launch …

COVID-19: Nasal vaccine's phase 3 trial completed, informs Bharat Biotech chief
2 years, 6 months ago

COVID-19: Nasal vaccine's phase 3 trial completed, informs Bharat Biotech chief

Firstpost  

Dr Krishna Ella said that the company will submit its data with Drugs Controller General of India next month and If everything is okay, it will be the world’s first clinically proven nasal COVID-19 vaccine Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said that the clinical phase III trials of the COVID-19 nasal vaccine have …

Covid Vaccine Immunity Wanes Faster in Cancer Patients, Boosters Are Best Shot: UK Study
2 years, 7 months ago

Covid Vaccine Immunity Wanes Faster in Cancer Patients, Boosters Are Best Shot: UK Study

News 18  

Some cancer patients are showing a rapid decline in Covid-19 vaccine effectiveness by three to six months compared to the general population, says a large-scale study carried out by the UK Coronavirus Cancer Evaluation Project, stressing on the importance of booster doses for those battling the malignant disease. They also found that vaccines offered higher protection against Covid-associated hospitalisation than …

India’s ‘other’ COVID vaccines: Status of under-trial & approved but unused jabs
2 years, 7 months ago

India’s ‘other’ COVID vaccines: Status of under-trial & approved but unused jabs

The Hindu  

As India nears the 200-crore COVID-19 vaccination mark, Serum Institute of India’s Covishield accounts for 80 per cent of the jabs, while Bharat Biotech’s Covaxin accounts for 16.75 per cent jabs. As of date, India has granted emergency usage authorisation to nine COVID-19 vaccine candidates in total – Covishield, Covaxin, Covovax, Corbevax, Zydus Cadila’s ZyCoV-D, Moderna’s Spikevax, Sputnik-V, Sputnik Light, …

Gap Between 2nd Covid Vaccine, Booster Dose Reduced To 3 Months For Those Travelling Abroad
2 years, 7 months ago

Gap Between 2nd Covid Vaccine, Booster Dose Reduced To 3 Months For Those Travelling Abroad

ABP News  

New Delhi: The government has now reduced the gap between second Covid-19 vaccine jab and booster dose to a minimum of 90 days for those travelling abroad, news agency PTI reported quoting official sources on Wednesday. Those who need to travel overseas can take the booster dose of Covid vaccine as required by the country they are travelling to before …

Discover Related